Atomoxetine/trazodone - Apnimed
Alternative Names: AD-504; Trazodone/atomoxetineLatest Information Update: 23 Aug 2022
At a glance
- Originator Apnimed
- Class Piperazines; Propylamines; Pyridines; Sleep disorder therapies; Small molecules; Triazoles
- Mechanism of Action Adrenergic uptake inhibitors; Alpha adrenergic receptor agonists; Serotonin 2A receptor antagonists; Serotonin 2C receptor antagonists; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Sleep apnoea syndrome
Most Recent Events
- 03 Aug 2022 Apnimed completes a phase-II MARIPOSA clinical trial in Sleep apnoea syndrome (Combination therapy) in USA (PO) (NCT05071612)
- 02 Jun 2022 Efficacy and adverse events data from a phase II trial in Obstructive sleep apnea released by Apnimed
- 01 Dec 2021 Phase-II clinical trials in Sleep apnoea syndrome (Combination therapy) in USA (PO) (NCT05071612)